ShiftLeft to Present at No Hat Conference 2021
17.11.2021 11:00:00 EET | Business Wire | Press release
ShiftLeft, Inc., an innovator in automated application security testing, today announced that its Chief Scientist, Fabian Yamaguchi, and Security Research Engineer, Claudiu-Vlad Ursache, will give a presentation focused on Ghidra2cpg at the No Hat Conference in Bergamo, Italy on November 20, 2021. The No Hat 2021 is a security conference organized to bring together specialists, professionals and hobbyists operating in the field of computer security and privacy.
Event Details:
Who: Fabian Yamaguchi, Chief Scientist and Claudiu-Vlad Ursache, Security Research Engineer, ShiftLeft
What: Virtual Session: Presentation on Ghidra2cpg: From graph queries to vulnerabilities in binary code
When: Saturday, November 20, 2021, 11:15am – 12:00pm CET
Where: Centro Congressi Giovanni XXIII - Bergamo, Italy
For more information, visit: https://www.nohat.it/program
Session Abstract - Ghidra2cpg: From graph queries to vulnerabilities in binary code
Uncovering bugs in source code is hard enough as it is, but when all you have is a binary, the importance of tooling becomes undeniable. Disassemblers such as IDA Pro, Ghidra, BinaryNinja or Radare2 provide a strong foundation for an investigation but are designed primarily to assist in what remains a manual investigation. This leaves room for partial automations that make the discovery process less painful.
Fabian and Claudiu were looking to design a search tool for binary code that allows them to uncover instances of programming patterns linked to vulnerabilities - at scale and for multiple major instruction sets. In this talk, they will present ghidra2cpg, an extension for the open-source code mining platform Joern that enables it to process binary code. Together, Joern and ghidra2cpg enable you to quickly uncover the attack surface, search for variants of known vulnerabilities, and gather information interactively using a query language.
In this session they will show how to write queries for the system that describe bugs in source code and introduce corresponding queries for binary code, highlighting what's harder and what is easier to describe when looking at the machine code directly. They will also be looking at modern consumer-grade router firmware and may drop a zero-day or two in the process.
About Fabian Yamaguchi
Fabian is Chief Scientist at ShiftLeft Inc and an Associate Professor Extraordinary at Stellenbosch University. He has over 15 years of experience in the security domain, where he has worked as a security consultant and researcher, focusing on manual and automated vulnerability discovery. Throughout his work, he has identified previously unknown vulnerabilities in popular system components and applications such as the Microsoft Windows kernel, the Linux kernel, the Squid proxy server, and the VLC media player. He has presented his findings and techniques at both major industry conferences such as BlackHat USA, DefCon, First, and CCC, and renowned academic security conferences such as ACSAC, Security and Privacy, and CCS. He holds a master’s degree in computer engineering from Technical University Berlin, as well as a PhD in computer science from the University of Goettingen.
About Claudiu-Vlad Ursache
Claudiu-Vlad Ursache is a Security Research Engineer at ShiftLeft, having recently entered cybersecurity after a decade of writing software. In his day-to-day job he builds static analysis tools and his current research focuses on IoT firmware.
About ShiftLeft
ShiftLeft enables software developers and application security teams to radically reduce the attackability of their applications by providing near-instantaneous security feedback on software code during every pull request. By analyzing application context and data flows in near real-time with industry leading accuracy, ShiftLeft empowers developers and appsec team to find and fix the most serious vulnerabilities faster. Using its patented graph analysis that combines code attributes and analyzes actual attack paths based on real application architecture, ShiftLeft’s platform scans for attack context and pathways typical of modern applications, across APIs, OSS, internal microservices and first-party business logic code, and then provides detailed guidance on risk remediation within existing development workflows and tooling. ShiftLeft CORE, a unified code security platform, combines the company’s flagship NextGen Static Analysis (NG SAST), Intelligent Software Composition Analysis (SCA), and contextual security training through ShiftLeft Educate to provide developers and application security teams the fastest, most accurate, most relevant, and easiest to use automated application security and code analysis platform.
Backed by Bain Capital Ventures, Mayfield, Thomvest Ventures, and SineWave Ventures, ShiftLeft is based in Santa Clara, CA. To learn how ShiftLeft keeps AppSec in sync with the rapid pace of DevOps, see https://www.shiftleft.io/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005403/en/
Contact information
PR:
Corinna Krueger
ShiftLeft
ckrueger@shiftleft.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
